Type 2 Diabetes and Brain Health: What Recent Studies on Blood Sugar and Medications Can—and Cannot—Tell Us
Type 2 diabetes is often discussed through blood glucose, weight, A1c, blood pressure, or cholesterol. Those measures matter. But people living with diabetes are also asking a broader question: What does metabolic health mean for the brain over time? Brain health belongs in the type 2 diabetes conversation That question has become more urgent as […]
Earlier Risk Stratification in Diabetic Kidney Disease May Help Teams Target Care—What a New Real-World Study Shows
Kidney disease is one of the most serious complications associated with type 2 diabetes, yet it can progress quietly. A person may feel well while urine albumin changes, estimated glomerular filtration rate (eGFR) declines, blood pressure rises, or cardiovascular risk increases. That is why early screening and risk assessment matter. They give the care team […]
A Sorbitol Study Is Raising New Questions About Gut Microbes and Fatty Liver—But It Was Not a Human Trial
A headline about a “diabetic-friendly” sweetener harming the liver is designed to get attention. It can also leave people with type 2 diabetes wondering whether a piece of sugar-free gum, a product labeled “no sugar,” or fruit is suddenly dangerous. The honest answer is more useful than the alarming one: a new study raises an […]
Digital Diabetes Care Is Expanding Around GLP-1s. The Real Test Is Whether Support Extends Beyond the Prescription.
GLP-1 medicines are changing more than medication lists. They are changing the market for diabetes support. Employers, health plans, clinicians, and patients are all asking versions of the same question: if a person starts a GLP-1 medicine, what happens around the prescription? Who helps them understand side effects, protect nutrition, stay active, navigate coverage, monitor […]
Food Is Medicine Works Best When It Is Built Into Care—not Added as an Afterthought
“Food is medicine” is an appealing phrase because it names something many people living with type 2 diabetes already know: food choices are not a side note. They affect energy, glucose patterns, blood pressure, lipids, sleep, and the routines that make treatment sustainable. But the phrase can also become vague. Telling someone to “eat better” […]
A GLP-1 Prescription Is Not a Complete Care Plan: What Responsible Evaluation and Follow-Up Look Like
GLP-1 medicines have become a major part of conversations about weight, blood sugar, and metabolic health. That visibility has created opportunity: some people who once felt shut out of care are now asking better questions about diabetes, obesity, and long-term risk. It has also created a problem. A medication can be presented online as if […]
A One-Time Gene Therapy for Diabetic Retinopathy? What Is Known—and What Is Still Investigational
Diabetic retinopathy is a diabetes complication that affects the blood vessels of the retina, the light-sensitive tissue at the back of the eye. It can progress without noticeable symptoms in its early stages, which is why regular eye screening matters even when vision seems normal. A recent company announcement described follow-up results from a study […]
Akkermansia and Type 2 Diabetes: Promising Microbiome Science, Not a Supplement Prescription
The human gut contains a large and diverse community of microorganisms. Researchers are increasingly interested in how this ecosystem interacts with digestion, immune signaling, medications, body weight, and metabolic health. One bacterium that appears frequently in this research is Akkermansia muciniphila. Akkermansia lives in the mucus layer of the intestine and has been associated, in […]
Semaglutide and Fatty Liver Disease: What the MASH Evidence Actually Shows
Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of fatty liver disease in which excess fat in the liver is accompanied by inflammation and liver-cell injury. Over time, some people develop fibrosis, or scarring, which can progress to cirrhosis and other serious complications. Why MASH matters in a type 2 diabetes conversation MASH is closely […]
GLP-1s After 60: Why Medication Decisions Must Protect Strength, Function, and Independence
Source note: This article was prompted by reporting on GLP-1 medicines and aging, plus a commentary on the history of weight-loss culture. The question is not simply “Will it cause weight loss?” GLP-1 receptor agonists have changed the conversation around obesity and type 2 diabetes. These medicines can improve glucose control in people with type […]